CN1048399C - Novel levamisole liniment - Google Patents
Novel levamisole liniment Download PDFInfo
- Publication number
- CN1048399C CN1048399C CN94103359A CN94103359A CN1048399C CN 1048399 C CN1048399 C CN 1048399C CN 94103359 A CN94103359 A CN 94103359A CN 94103359 A CN94103359 A CN 94103359A CN 1048399 C CN1048399 C CN 1048399C
- Authority
- CN
- China
- Prior art keywords
- liniment
- levamisole
- chloride
- camphora
- boric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000865 liniment Substances 0.000 title claims abstract description 25
- 229940040145 liniment Drugs 0.000 title claims abstract description 22
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 title claims description 22
- 229960001614 levamisole Drugs 0.000 title claims description 22
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000001110 calcium chloride Substances 0.000 claims abstract description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 9
- 239000001103 potassium chloride Substances 0.000 claims abstract description 9
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- 239000004327 boric acid Substances 0.000 claims description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- 229940025250 camphora Drugs 0.000 claims description 9
- 239000010238 camphora Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- -1 Oleum Caryophylli Chemical compound 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 1
- 229960002217 eugenol Drugs 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 abstract description 8
- 208000003251 Pruritus Diseases 0.000 abstract description 7
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 239000010634 clove oil Substances 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002371 mycocidal effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A levo-imidazole liniment for preventing and treating hepatitis B is prepared from existing liniment through changing its prescription, adding clove oil, camphor, sodium chloride, potassium chloride and calcium chloride, and features no by-effect of local dermatitis and pruritus. The novel liniment has simple preparation method and reliability, and is a great improvement on the original liniment.
Description
The present invention relates to a kind of liniment that adopts the new prescription of levamisole and preparation method thereof, particularly liniment of the new prescription of levamisole of disease such as treatment hepatitis B and preparation method thereof.
Levamisole is a kind of abbreviation, its chemistry is called L-(-)-2,3,5,6-tetrahydrochysene-6-phenylimidazole (2,1-β)-thiophene miaow list hydrochloric acid (L-(-)-2,3,5,6-tetrahydro-6-phenylimidazo (2,1-β)-and thiazol, be that discovery in 1971 has the immunostimulation that bacillus infection is produced in anti-current to mice monohydrochloride), thereby cause the interest of people its therapeutical effect.Then occurring the employing levamisole on the market as the anthelmintic oral medicine of animal, occurring oral medicine subsequently again as the hepatitis B of treatment human body.Along with the further investigation of people to its therapeutical effect, had as liniment now, be used for treating sick new drug such as hepatitis B outward, these liniment new drugs can be divided into three major types substantially.
That is: (1) levamisole-diformazan wind liniment
(2) levamisole-boric acid, ethanol liniment
(3) levamisole-isopropyl alcohol liniment
The inventor is in research in 1986 and the levamisole smears identified by rear-service department of Nanjing Military Command Ministry of Public Health, and its prescription is levamisole and boric acid, ethanol system.
This levamisole smears is produced in batches and is sold in Meifeng Pharmaceutical Factory Fuzhou City subsequently.
But the common drawback of above-mentioned these liniments is, some patient can cause dermatitis after applying ointment, as red and swollen, itch, severe patient has to stop to be coated with put on the skin the good opportunity of the treatment of letting sth. slip by.
The object of the present invention is to provide a kind of levamisole liniment of modified form, be characterized in can not causing stimulation to skin, being coated with the position redness can not take place, do not itch, to very effective novel levamisole liniments such as chronic inflammatory disease such as treatment hepatitis B, upper respiratory tract infection, bronchial asthma and cervical erosion and rheumatoid arthritiss.
Another object of the present invention is to provide a kind of preparation method of novel left-handed liniment:
Embodiment of the present invention are as follows:
(1) prescription: (following) all in weight portion
Levamisole list hydrochloric acid 80-120
Boric acid 25-35
Oleum Caryophylli 0.4-0.8
Camphora 0.3-0.7
Sodium chloride 7-9
Potassium chloride 2-4
Calcium chloride 2-4
Distilled water 650-750
30% isopropyl alcohol adds to and is total up to 1000 weight portions.
The purpose that adds Oleum Caryophylli has 2 effects, and the 1st, it has mycocidal effect; The 2nd, be to have the anti-inflammatory anti-itch effect, thereby prevented skin allergy behind the coating that Pruritus takes place and the phenomenon of red clock occurs, it can play synergism with Camphora, plays beyond thought antianaphylaxis function.
The effect that camphorates is to make levamisole be spread in skin rapidly equably, makes levamisole more effective and play a role rapidly, and Camphora has blood vessel dilating and has taste preferably simultaneously, thereby improves curative effect and the patient is easy to accept this liniment.
The effect that adds sodium chloride, potassium chloride, calcium chloride is: improve curative effect owing to can in time replenish trouble shortage sodium, potassium, these cationes of calcium.As for isopropyl alcohol is transdermal agent, and levamisole has been the treatment component, and boric acid has disinfective action, and these three kinds is prior art.
(2) preparation method
Earlier in a general heating container, add distilled water, drop into sodium chloride, potassium chloride, calcium chloride, Oleum Caryophylli, boric acid then, stir and heating under 30～50 ℃, it is fully dissolved, add levamisole and Camphora again, add isopropyl alcohol to 1000 milliliter at last, refilter, the filtrate packing filling bottle of sterilizing forms.
Following preference elaborates to the present invention, but does not mean that limitation of the present invention.
Example 1: 670 milliliters of the distilled water of adding weighing in one 1500 milliliters the general glass container that has stirring, drop into sodium chloride 7 grams, potassium chloride 2 grams, calcium chloride 2 grams, add boric acid 27 grams and Oleum Caryophylli 0.5 gram again, temperature be 32 ± 1 ℃ and stir under material is fully dissolved, add levamisole 85 grams again, Camphora 0.4 gram, continue to remain on 32 ± 1 ℃ and stirring fully dissolving down, add 206.1 milliliters of isopropyl alcohols at last again, altogether 1000 milliliters of medicinal liquids, under universal filter, filter, 985 milliliters of filtrates, carrying out conventional sterilization and packing, to get every bottle be 5 milliliters liniment of the present invention 197 bottles.
Example 2: remove prescription and change levamisole 110 grams into, sodium chloride is 9 grams, potassium chloride is that 4 grams, calcium chloride are 4 grams, and boric acid is 32 grams, and Oleum Caryophylli is 0.8 gram, Camphora is 0.7 gram, distilled water is that 720 grams and isopropyl alcohol are outside 119.5 milliliters, and all the other conditions are identical with example 1, make 985 milliliters of liniments of the present invention equally, sterilization packing 197 bottles, 5 milliliters every bottle.
Clinical example 1: the king * *, man 46 years old, asymptomatic hepatitis B antigen carrier is put medicine of the present invention weekly on the skin 1～2 time, directly medicine is dropped on the arm each 2 milliliters, continuous 6 months, judge its curative effect with the feminine gender of blood serum designated object HBSAg and HBeAg, and patient's whole body or part has or not adverse side effect behind the observation coating, whether special survey has or not erythra symptom such as scratch where it itches, the result is that HBSAg and HBeAg turn out cloudy simultaneously, does not see that part and whole body have adverse side effect, follows up a case by regular visits to and changes sun in 18 months.
Clinical example 2: poplar * *, woman 27 years old, be four months pregnant, healthcare hospital for women ﹠ children checks and finds hepatitis B antigen e antigen positive, puts on the skin by clinical example 1 method and amount and be coated with dispenser, check HBSAg and HBeAg turn out cloudy before the childbirth, give birth to the baby and also do not infect hepatitis B virus, also do not find vomiting, feel sick, dizziness and whole body and local the appearance are with the bad side reaction that oral administration was gone out.
Advantage of the present invention:
1. to sick therapeutic actions and the existing levamisol of selling such as hepatitis B Liniment is identical. Find no difference.
2. allergy is not taken place for whole body and part, such as redness, it is existing to scratch where it itches etc. Resemble.
3. method for making is simple and reliable, product stability is high.
Claims (3)
1. levamisole liniment, its treatment component contains L-(-)-2,3,5,6-tetrahydrochysene-6-phenylimidazole (2,1-β) thiazole list hydrochloric acid, isopropyl alcohol and boric acid is characterized in that also containing in this liniment sodium chloride, potassium chloride, calcium chloride, Oleum Caryophylli, Camphora.
2. according to claim 1 and liniment, it is characterized in that the proportioning (weight portion) of each component is as follows:
Levamisole 80-120
Boric acid 25-35
Oleum Caryophylli 0.4-0.8
Camphora 0.3-0.7
Sodium chloride 7-9
Potassium chloride 2-4
Calcium chloride 2-4
Distilled water 650-750
30% isopropyl alcohol is mixed with 1000 weight portions.
3. the preparation method of a levamisole liniment is characterized in that:
(1) earlier sodium chloride, potassium chloride, calcium chloride, Oleum Caryophylli and boric acid are added in the distilled water 650-750 weight portion 30～50 ℃ of following stirring and dissolving by the amount of claim 2,
(2) add levamisole and Camphora 30～50 ℃ of following stirring and dissolving by the amount of claim 2 again,
(3) add isopropyl alcohol to 1000 weight portion again,
(4) filter sterilization and packing filling bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103359A CN1048399C (en) | 1994-04-04 | 1994-04-04 | Novel levamisole liniment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103359A CN1048399C (en) | 1994-04-04 | 1994-04-04 | Novel levamisole liniment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1099616A CN1099616A (en) | 1995-03-08 |
| CN1048399C true CN1048399C (en) | 2000-01-19 |
Family
ID=5031021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94103359A Expired - Fee Related CN1048399C (en) | 1994-04-04 | 1994-04-04 | Novel levamisole liniment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1048399C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3759714B2 (en) * | 2001-12-27 | 2006-03-29 | 株式会社資生堂 | Itching, rough skin, sensitive skin and whitening agent by inhibiting production and release of stem cell factor |
| CN1197573C (en) * | 2003-02-14 | 2005-04-20 | 朱钦文 | Liniment of levamisole hydrochloride |
-
1994
- 1994-04-04 CN CN94103359A patent/CN1048399C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 《中药大辞典》第一版 1986.5.1 江苏新医学院编，上海科学技术出版社 * |
| 《煤矿医学》1983,5(3) 1983.3.1 李冠兰，"左旋咪唑治疗慢性肝炎的免疫学机理";《中药大辞典》第一版 1986.5.1 江苏新医学院编，上海科学技术出版社 * |
| 《煤矿医学》1983,5(3) 1983.3.1 李冠兰，"左旋咪唑治疗慢性肝炎的免疫学机理" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1099616A (en) | 1995-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| AU2002343270B2 (en) | Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties | |
| CN1048399C (en) | Novel levamisole liniment | |
| CN113546089B (en) | Application of 1-ethyl-3, 7-dimethyl xanthine in preparation of medicine for treating pneumonia | |
| CN103230404A (en) | Novel use of adefovir dipivoxil or medicinal salt thereof | |
| CN114504578A (en) | Drugs for the treatment and prevention of related diseases caused by viral infections and their uses | |
| CN116531410B (en) | Application of staphylococcus albus in preparation of composition | |
| CN113521248A (en) | Application of a probiotic active peptide in the preparation of medicine, food or health care product with the effect of preventing or treating diarrhea | |
| CN1557479A (en) | Interferon liposome emulsifiable paste | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| Sankhe et al. | A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID-19 patients | |
| US20030207819A1 (en) | Compositions and methods for treating inflammatory connective tissue diseases | |
| CN116672355A (en) | Application of carboxymethyl xylan zinc complex in health care medicine or food | |
| TW581675B (en) | A pharmaceutical composition for use in preventing the onset of asthma in a patient | |
| CN1583108A (en) | Health care product of hippophae rhamnoides oil | |
| CN113521057B (en) | Blood sugar reducing composition containing genistein and application thereof | |
| CN111358782A (en) | Application of imipenem in preparation of medicine for treating inflammatory storm caused by infectious diseases | |
| WO2020020317A1 (en) | Metformin compound composition and use thereof | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| WO2021211085A1 (en) | Method of preventing and treating diseases caused by enveloped viruses, including coronaviruses (variants), and a set of pharmaceutical preparations for implementing said method | |
| CN117695304A (en) | Application of snow Yan Duotang in preparation of medicines for preventing or treating inflammatory bowel disease | |
| CN1279067A (en) | Defervescent picking for baby | |
| CN1256100C (en) | Artificial bear gall | |
| Watson et al. | Lidocaine absorption and metabolism after oropharyngeal application in young and young-elderly adults | |
| CN1084622C (en) | Pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhu Qinwen Document name: Notification to Pay the Fees |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhu Qinwen Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |